BB Biotech AG publishes its interim report

EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report
BB Biotech AG publishes its interim report

26-Apr-2024 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc announcement pursuant to Art. 53 LR

April 26, 2024

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at
March 31, 2024, which covers the results of its business activities for the
first three months of 2024.

Based on the consolidated accounts of BB Biotech AG, net profit for the
period ended March 31, 2024 amounted to CHF 260 mn (loss of CHF 254 mn in
the same period 2023). For an investment company, the results reflect the
share price development of the companies held in the portfolio.

The interim report as at March 31, 2024, is available under
report.bbbiotech.ch/Q124 or www.bbbiotech.com.

For further information:

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch

www.bbbiotech.com

Company profile
BB Biotech AG is an investment company with its registered office in
Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges.
It has invested in innovative drug developers headquartered primarily in the
US and Western Europe. BB Biotech is one of the world's largest investors in
this sector. The competent Board of Directors with its long-standing
experience set the investment strategy and guidelines. Investment decisions
are taken by the experienced investment management team of Bellevue Asset
Management AG based on their extensive investment research.


End of Inside Information

---------------------------------------------------------------------------

26-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        BB BIOTECH AG
                   Schwertstrasse 6
                   8200 Schaffhausen
                   Switzerland
   Phone:          +41 52 624 08 45
   E-mail:         info@bbbiotech.com
   Internet:       www.bbbiotech.ch
   ISIN:           CH0038389992
   WKN:            A0NFN3
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Mailand, SIX
   EQS News ID:    1889669

End of Announcement EQS News Service
---------------------------------------------------------------------------

1889669 26-Apr-2024 CET/CEST